Regulatory changes in Europe and the UK

Too few qualified paediatric pharmacology investigators to plan and conduct studies. 

Countries in Europe, particularly the UK, are following the positive steps of the USA a number of regulatory proposals and initiatives have been carried out in an effort to deal with the lack of drng information and dosage forms for children. 

Increase the availability of medicines specifically adapted and licensed for use in children. 

Increase the information available to the patient/carer and prescriber about the use of medicines in children, including clinical trial data. 

Lead to an increase in high-quality research into medicines for children. 

---